Sign up
Pharma Capital

Imagion Biosystems pioneering medical imaging with 'printer and ink' business model

Imagion Biosystems (ASX:IBX) president and CEO Bob Proulx tells Proactive Investors that the company is commercialising a new form of medical imaging that it developed for the early, non-invasive detection of cancer that uses biosafe nano-particles.

Proulx explains the medical case as well as the business case behind the technology, saying "in the medical imaging space today there's no consumable that goes with it... with our technology, because it includes both the measuring instrument and an injectable component, there's the classic printer-ink business model. We think that will be attractive for our commercial partner because now you'll be able to not only sell and install and service the instrument, but you'll also have the consumable that goes with each of the new tests that we bring to market."

 

View full IBX profile View Profile
View All

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.